Intersectin 1 (ITSN1) Identified by Comprehensive Bioinformatic Analysis and Experimental Validation as a Key Candidate Biological Target in Breast Cancer

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s216286
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Comprehensive Characterization of the DNA Amplification at 13q34 in Human Breast Cancer Reveals TFDP1 and CUL4A as Likely Candidate Target Genes

Breast Cancer Research
Cancer ResearchOncology
2009English

ICAM-1 as a Molecular Target for Triple Negative Breast Cancer

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2014English

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer

Scientific Reports
Multidisciplinary
2019English

Identification of Key Candidate Genes for Pancreatic Cancer by Bioinformatics Analysis

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2019English

Mp84-20 Bioinformatic Analysis Utilizing the Androgenic Suppressive Effect Identified Promising Candidate Drugs for Reprogramming Docetaxel-Resistant Castration-Resistant Prostate Cancer

Journal of Urology
Urology
2016English

Lipoprotein Lipase as a Candidate Target for Cancer Prevention/Therapy

Biochemistry Research International
Biochemistry
2012English

Identification of New Candidate Therapeutic Target Genes in Triple-Negative Breast Cancer

Genes and Cancer
Cancer ResearchGenetics
2012English

PLXNA2 Identified as a Candidate Gene by Genome-Wide Association Analysis for Mandibular Prognathism in Human Chondrocytes

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2018English

Identification of Tumorigenicity-Associated Genes in Osteosarcoma Cell Lines Based on Bioinformatic Analysis and Experimental Validation

Journal of Cancer
Oncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy